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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not
vitamin D is an effective treatment method in reducing mortality due to cardiovascular disease.
STUDY DESIGN: A review of two double blind, randomized controlled trials (RCTs) and one
randomized open-label study published in the English language after 2008. The articles
compared oral, intramuscular, or oil drops of vitamin D to a placebo group.
DATA SOURCES: One double-blind randomized controlled trial, one randomized control trial
that was not blinded, and one randomized open-label study were found using PubMed, Medline,
Embase, or Cochrane. The articles were selected based on their correlation to the specified topic,
date of publications, and their evaluation of POEMs.
OUTCOMES MEASURED: The effect of vitamin D supplementation on reducing mortality in
patients with cardiovascular disease will be measured. Mortality was measured by main cause of
death from death registrations, Rankin scales, repeated contacts with the participants, contact
with family physicians, regular review of medical records, and consultation of the respective
registration office.
RESULTS: Two studies used in this review showed no significant improvement in vitamin D
allocation in the reduction of mortality due to cardiovascular disease while one found clinical
significance in the allocation of vitamin D. Avenell et al. and Zittermann et al.’s studies were not
able to demonstrate an improvement in vascular mortality or all-cause mortality respectively
with vitamin D supplementation. Gupta et al. reported a potential benefit in ischemic stroke
survivors with vitamin D insufficiency or deficiency with the supplementation of vitamin D and
calcium. This is the only RCT that did not separate calcium and vitamin D supplementation and
instead combined both which showed a trend towards reduction in mortality.
CONCLUSIONS: The results of these studies showed no significant improvement in vitamin D
allocation alone to reducing cardiovascular death. Although Gupta et al. reported a statistically
significant lower mortality rate in the treatment arm compared to the placebo, it did not separate
vitamin D allocation from calcium therefore we cannot assume that vitamin D supplementation
alone reduced death from cardiovascular disease. Future studies should be conducted when
vitamin D supplementation is given before a major cardiovascular event such as a stroke or heart
failure.
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INTRODUCTION
Cardiovascular disease (CVD) is a broad term that encompasses different types of
diseases. CVD can include diseases such as: hypertension; coronary heart disease, including
myocardial infarction, angina pectoris, and heart failure; cerebrovascular disease, including
stroke and transient ischemic attack; peripheral artery disease including intermittent claudication;
and aortic atherosclerosis and thoracic or abdominal aortic aneurysm. Heart disease is the leading
cause of death for both women and men a year, accounting for about 1 in 4 deaths, and with
about 610,000 people dying of heart disease in the United States every.1,2 The incidence of CVD
continues to increase as the five leading modifiable risk factors (hypercholesterolemia, diabetes,
hypertension, obesity, and smoking) continue to be major risk factors in today’s society.2 It is
estimated that these risk factors are responsible for more than half of cardiovascular mortality.
Lifetime risk of overall cardiovascular heart disease has begun to approach 50 percent for
persons age 30 years and up with no known cardiovascular disease.1 In 2016, cardiovascular
disease cost America $555 billion. By 2035, the cost is estimated to skyrocket to $1.1 trillion. 3
According to the CDC, 6.7% of office-based physician visits were for coronary artery
disease, ischemic heart disease, or history of myocardial infarction.2 Five and nine tenths percent
of visits to the emergency departments included a diagnosis of coronary artery disease, ischemic
heart disease, or myocardial infarction.2
Cardiovascular disease is caused by underlying atherosclerosis. The dysfunction of the
endothelial layer is thought to be the initial step in atherosclerosis and is thought to be caused by
loss of endothelium-derived nitric oxide which can cause a loss of vasodilation of the vessels.
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Inflammation is also a crucial step of the buildup of atherosclerosis in which
macrophages that have been taken up by oxidized LDL, also known as “foam cells,” release
inflammatory factors including growth factors, cytokines, and other inflammatory substances.
These inflammatory factors can act on smooth muscle cells and other pro-inflammatory
cytokines to induce cell proliferation. Intracellular lipids, extracellular deposits and T
lymphocytes accumulate early within the intimal layer of the blood vessel forming a fatty streak.
As the fatty streak begins to expand, smooth muscle cells accumulate in the intima. As the
smooth muscle cells undergo apoptosis within the fatty streak, this begins to increase the amount
of macrophage accumulation and micro-vesicles that can calcify and in turn leading to the
formation of atherosclerotic plaques.1 As aging takes place, the lesions begin to progress to
plaques in early adulthood and accumulate to thrombotic occlusion acute cardiovascular events
in middle age and later adulthood.
Cardiovascular disease of different origins can present in patients in many different
aspects. Generalized symptoms for cardiovascular disease can include chest pain and tightness,
shortness of breath, pain and numbness in distal extremities, lightheadedness, irregular
heartbeats, dizziness, edema in the hands, ankles, or feet, and headaches. Although
cardiovascular disease continues to be prevalent in today’s society, there are many nonpharmaceutical and pharmaceutical methods that could assist with the management of
cardiovascular disease. Lifestyle and diet modifications such as exercising regularly, smoking
cessation, and decreasing fatty and processed foods intake with an increase in fruits and
vegetables are the initial steps in management. Pharmacological agents such as diuretics, ACE
inhibitors, angiotensin II receptor blockers, calcium channel blockers, beta blockers, and statin
therapy can all assist in managing cardiovascular disease.1 Currently, there is no definitive cure
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for cardiovascular disease however the medications listed as well as lifestyle modifications and
controlling underlying conditions have improved symptoms in individuals with cardiovascular
disease. Vitamin D may assist in reducing mortality among these patients although many
systematic reviews have not been done to prove any correlation. Vitamin D is able to decrease
prostaglandins, COX-2, and pro-inflammatory cytokines to reduce inflammation
decrease calcium cellular influx while increasing matrix Gla protein, which inhibits vascular
calcification and smooth muscle proliferation. It is also able to decrease renin in turn regulating
blood pressure and volume homeostasis.8 Reduction in the formation of atherosclerotic plaques
and smooth muscle proliferation leading to endothelial damage can lead to a decrease in all
forms of cardiovascular disease. More recent studies have been investigating if vitamin D
supplementation may be used as an oral, intramuscular (IM), or in the form of oil drops
supplementation to decrease morbidity and mortality associated with cardiovascular disease.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not vitamin D is
an effective treatment method in reducing mortality in patients who have cardiovascular disease.
METHODS
All three articles were researched using PubMed, Medline, Embase, or Cochrane and
were chosen based on their clinical relevance to the research question and their patient-oriented
outcomes. The key words used to research these articles included “vitamin D”, “cardiovascular
diseases”, and “mortality.” All of the articles included in this review are published in the English
language after 2008. Inclusion criteria included human studies that were randomized and
controlled, in the English language, and on the subject of humans while studies published more
than 10 years ago and articles on other species were excluded. The summary of statistics
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included numbers needed to treat (NNT), RBI, CER, EER, ABI, and P-values. Three randomized
controlled trial studies on the use of vitamin D supplementation (orally, IM, or oil drops) on
adults aged 18 and over with ischemic stroke, fractures, vascular diseases, and heart failure were
studied in this analysis (Table 1). All three trials compared a treatment group receiving vitamin
D supplementation to the experimental group who received no vitamin D supplementation or
usual care for their underlying disease. The outcomes of these articles focused on decrease in
mortality in cardiovascular disease patients with vitamin D supplementation. The results were
measured by main cause of death from death registrations, Rankin scales, repeated contacts with
the participants, contact with family physicians, regular review of medical records, and
consultation of the respective registration office.
OUTCOMES MEASURED
The outcomes that were measured were based on a Patient Oriented Evidence that
Matters (POEM). This EBM review measured the effect of vitamin D supplementation on
reducing mortality in patients with cardiovascular disease.
Avenell et al. used vascular disease mortality from data that was derived only from main
cause of death from death registrations that were collected through the national United Kingdom
databases of the General Register of Scotland and the National Health Service Medical Research
Information Service.5 Zitterman et al. tested for all-cause mortality as well, which was measured
by repeated contacts with the participants, contact with family physicians, regular review of
medical records, and consultation of the respective registration office.6 Gupta et al. used the
Modified Rankin scale Scale (mRS) at 3 months and 6 months post stroke.7 The mRS
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Table 1. Demographics and Characteristics of Included Studies
Study
Type
#
Age
Inclusion
Exclusion
pts
Criteria
Criteria
UK residents
Avenell,5
RCT 5292 70
Fragility
(2011)
and
fracture within with cancer
likely to
above the last 10
years and aged metastasize,
bedbound before
at least 70
fracture, mental
years old.
test below 7

W/D

Interventions

0

2 tablets daily
with meals
containing a
total of 800 IU
(20
micrograms)
of vitamin D3

(total=16), life
expectancy less
than 6 months,
not taking more
than 200 IU of
vitamin D
treatment, or any
vitamin D
metabolite in the
last 5 years

Zittermann,6
(2017)

RCT

Gupta7(2016) RCT

400

73

18-79 18-79 years of
age, HF
patients
classified as
having New
York Heart
Association
Functional
Class II or
higher who
were in a
long-term
program for
heart
transplantation
60.4
Within 7 days
+/of onset of
11.3
first stroke,
yrs
prestroke
modified
Rankin score
of <2, age >/=
35

“High urgent”
0
listing for heart
transplantation,
supplemental
vitamin D
intake >800
IU/d, and
baseline 25hydroxyvitamin
D levels greater
than or equal to
75 nmol/L.

4000 IU
vitamin D3
daily

Patients already 12
on vitamin D
and calcium
supplements,
renal and
hepatic
impairment,
those who
underwent
thrombolysis

Single IM
injection of
600,000 IU
cholecalciferol
followed by
oral
cholecalciferol
60,000 IU
once a month
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measures the degree of dependence or disability in the daily activities of people who have
suffered a stroke or other causes of neurological disability. For this systematic review, the
Modified Rankin scale score of 6 was used as a validating measure signifying death in these
stroke patients.
RESULTS
This review included 3 randomized control trials to assess the effect of vitamin D
supplementation on cardiovascular mortality. The inclusion and exclusion criteria for all three
trials can be found in Table 1 above.
Avenell et. al selected 5,292 people with a mean age of 77 of whom 2,649 received
vitamin D3 supplementation and 2,643 were in the control group. Majority of the candidates in
the vitamin D and placebo groups had similar descriptions including being Caucasian female,
32% having a high risk for vitamin D deficiency, 12% being smokers, and equal percentages
having proximal femur, leg and pelvic or distal forearm fractures. Randomization was computer
generated, assigned into groups and minimized by age.5
Participants were randomized into 2 groups with one group receiving two tablets daily
with meals containing a total of 800 IU vitamin D3 and one receiving the placebo. The study
reported follow-up mortality data that had been notified through the trial and the 3-year followup period. During the trial and 3 years of follow-up, it was found that 32.4% (1,717) of the
5,292 died with the main cause of death being vascular disease for 42.3% (726) of the 1,717
participants. Vitamin D supplementation showed to only slightly reduce vascular death as 836
participants (31.6%) of the 2,649 participants allocated vitamin D died, compared with the 881
of the 2,643 (33.3%) participants not allocated vitamin D dying from vascular causes. The
reduction in mortality showed a confidence interval between 0.79 and 1.05 for the comparison of
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vitamin D administration vs. placebo in vascular death specifically with a p-value of 0.175. This
indicated there was not a statistically significant difference shown by a treatment effect with a
wide and imprecise confidence interval. The NNT calculated in this study was 100 making the
treatment effect very large. Table 2 of this review shows the CER, EER, RBI, ABI, and NNT
values. Compliance proved to be an issue in the study in which those returning questionnaires
showed the rate of pill takers had decreased to 67% at 12 months and 63% at 24 months.4 No
adverse health effects were noted in this RCT.
Table 2. Rate of Death Due to Vascular Disease in Placebo vs. Treatment Arms
CER
EER
RBI
ABI
NNT
0.142
0.132
-0.0704
0.01
100
Note: CER= Control Event Rate; EER= Experimental Event Rate; RBI= Relative Benefit
Increase; ABI= Absolute Benefit Increase; NNT= Numbers Needed to Treat
The double-blind randomized control study conducted by Zittermann et al. included
patients 18-79 years old that were classified as having New York Heart Association functional
class II or higher. These candidates were either listed as “elective” for heart transplantation or
were in a long-term program for heart transplantation. Of the 400 randomized candidates, 199
were allocated to receive 4000 IU vitamin D3 daily in the form of eight drops of an oily vitamin
D preparation known as Vigantol oil.6 The 201 candidates that were randomized to receive
placebo received a matching vitamin D- free oil daily (Migliol oil) during a meal. Concealment
in both parties was achieved by sequentially numbered drug containers.
Eighty-five candidates of the treatment arm and 84 candidates of the placebo arm
discontinued intervention due to center transfer, poor health condition, no pleasure to participate,
hypercalcemia, home-based care, and “other reasons.”6 Majority of the patients selected in the
study included males who suffered from dilated or ischemic cardiomyopathy with 80% having a
pacemaker and 41% having a baseline 25(OH)D level. The hazard ratio for the vitamin D
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versus placebo group was 1.09, which signifies a very slight difference in survival between the
two groups. The p-value found was 0.726 which proved to be statistically insignificant. Table 3
shows the change in all-cause mortality noted in both the placebo and vitamin D arms.
Table 3. Comparison in All-Cause Mortality in Vitamin D vs. Placebo6
Baseline
Vitamin 199
D
group
Placebo 201

194

188

180

174

166

166

Mortality
Rate
19.6%

194

185

180

174

166

160

17.9%

Gupta et al. conducted a randomized controlled open-label trial at a tertiary hospital that
included 53 patients that were equal or over the age of 35 of who presented within 7 days of
onset of first ever ischemic stroke and a pre-stroke modified Rankin score of less than 2.
Randomization was done by a random number generator on the computer. While the control
group received “usual post-stroke care alone,” which was not specified in the article, the
intervention group received a single intramuscular injection of 600,000 IU cholecalciferol
followed by 60,000 IU of oral cholecalciferol once a month with one-gram elemental calcium
daily along with usual poststroke care.7
Of the 53 randomized candidates, all of the candidates had a baseline vitamin D level less
than 75 nmol/L. The intervention arm began with 25 candidates while 4 were lost to follow-up
by 6 months. In comparison, the usual care arm began with 28 candidates while 5 were lost to
follow-up by 6 months. By 6 months, the intervention group had a total of 4 deaths as opposed to
11 total deaths in the usual post-stroke care alone group. Gupta et al. used an intention to treat
basis at the final follow-up with 11 patients (44%) having a “good outcome”, classified as a
modified Rankin score of 0-28, in the intervention arm; while 11 patients (39.3%) had a good
outcome in the usual care arm. The outcome analysis showed a decrease in mortality with
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vitamin D and calcium showed by Table 3. No adverse health effects were noted in this study
that directly correlated with vitamin D administration alone. Low calcium levels that were said to
be caused by vitamin D deficiency stimulated an excessive amount of parathyroid hormone
releasing resulting in a secondary hyperparathyroidism.7
Table 4. Outcome Comparisons in the Vitamin D plus Calcium Group vs. Treatment by Usual
Care Alone Group7
Outcome Vit. D
Usual
Difference Unadjusted P- value Adjusted P value
and
care
in %
OR/HR
OR/HR
Calcium
(95% CI) with 95%
with
CI
(95% CI)
Intention
to treat
Mortality
outcome
Death

N=25

N=28

N=25

N=28

-

-

-

-

-

4 (16%)

11
(39.3%)

-

0.34 (0.11.1)

.06

0.26
(0.080.9)

.03

DISCUSSION
The results from Avenell et al.’s study was not able to demonstrate an improvement in
vascular mortality with vitamin D supplementation. Although, Avenell et al.’s experimental
group proved to be the largest of the RCTs, the population was limited to Caucasian females
with a mean age of 77 who had a previous fracture 3 months or longer from enrollment.
Although there was no significant reduction in the mortality of the specified population used,
Avenell et al. stated that it is not known if these results would apply in younger people, older
people without a history of a fragility fracture, or high-risk populations in nursing homes. Other
limitations included variation in size and shape of the vitamin D and placebo tablets and lack of
concealment as a part of randomization in the trial which could lead to lack of validity in the
trial. On the other hand, Zittermann et al. had a strong representation of middle-aged males with
New York Heart Association Functional Class II heart failure. However, Zittermann et al. admits
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that enrollment did not reach the planned number of study participants and the annual mortality
was lower than originally expected therefore showing a low statistical power to assess an actual
significant difference between the experimental arm and placebo.5 Although both studies’ results
met the requirement for this systematic review, the specificity of each studies’ population could
be accounted as a limitation in both studies.
Gupta et al. reported a potential benefit in ischemic stroke survivors with vitamin D
insufficiency or deficiency with the supplementation of vitamin D and calcium. This is the only
RCT that did not separate calcium and vitamin D supplementation and instead combined both
which showed a trend towards improvement in disability. However, it is noted in the study that
the baseline differences in serum cholesterol because the supplemental arm had higher baseline
levels, dietary habits and level of outdoor physical activity, and prevalence of atherosclerosis,
which was not evaluated in detail in the study, were not considered and cannot be ruled out when
discussing trends towards disability in this article specifically. The randomization and allocation
were done by a single investigator and was not blinded which could have led to bias or other
study limitations.
The National Institute of Health recommended dietary allowances of vitamin D to be 600
IU in males and females aged 14-70 years old and 800 IU in males and females over the age of
70. Although rare, vitamin D toxicity can to hypercalcemia and other non-specific signs such as
weight loss, polyuria, anorexia, and heart arrhythmias.9
CONCLUSION
Based on the results of this systematic review, there is no significant improvement in
reducing mortality due to cardiovascular disease with vitamin D supplementation. Gupta et al.

Pendleton, Vitamin D for CVD 11
showed a potential benefit of vitamin D supplementation along with calcium supplementation in
reducing all-cause mortality in stroke victims.
Future studies should be conducted when vitamin D supplementation is given before a
major cardiovascular event such as a stroke or heart failure. Vitamin D supplementation in early
stages of cardiovascular disease such as hypertension should be studied to assess all causemortality with vitamin D supplementation over years rather than short time durations. Future
studies are warranted in a more diverse group of candidates and including ultraviolet light as a
possible supplement with dietary, intramuscular, or oral vitamin D supplementation. The use of
vitamin D early in cardiovascular disease can reduce cardiovascular complications and costs in
the long run for these patients.
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